PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
5.06
P/E of 5.06 versus zero earnings in Medical - Pharmaceuticals. Walter Schloss would verify earnings quality.
0.31
P/S less than half the Medical - Pharmaceuticals median of 6.71. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
0.72
P/B less than half the Medical - Pharmaceuticals median of 2.09. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-7.95
Negative FCF while Medical - Pharmaceuticals median P/FCF is -15.06. Seth Klarman would investigate cash flow improvement potential.
-14.46
Negative operating cash flow while Medical - Pharmaceuticals median P/OCF is -12.00. Seth Klarman would investigate operational improvement potential.
0.72
Fair value ratio less than half the Medical - Pharmaceuticals median of 2.09. Joel Greenblatt would investigate if this discount is justified.
4.94%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 0.02%. Joel Greenblatt would investigate if high yield reflects hidden value.
-12.57%
Negative FCF while Medical - Pharmaceuticals median yield is -1.69%. Seth Klarman would investigate cash flow improvement potential.